Brief: Biocartis Initiates Commercialization In Europe Of Hepatopredict Test For Liver Cancer Patients
10/10/2022 06:03
Oct 10 (Reuters) - Biocartis Group NV BCART.BR :
* REG-PRESS NEWS BIOCARTIS GROUP NV: BIOCARTIS INITIATES
COMMERCIALIZATION IN EUROPE OF HEPATOPREDICT (CE-IVD) TEST FOR
LIVER CANCER PATIENTS
Source text for Eikon: ID:nGNE4b97wL
Further company coverage: BCART.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biocartis NV
See all newsBrief: Biocartis Group NV Appoints Randy Polonsky As Chief Financial Officer
Brief: Biocartis Appoints New Chief Business Officer, VP Global Marketing
Brief: Biocartis And Merck To Collaborate
Brief: Biocartis's Secured Creditors Enforced Their Security Over Subsidiaries Shares
Brief: Biocartis Announces Expansion Of Its Collaboration With Apis Assay Technologies